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Fibrosis is a common condition that can affect all body tissues, driven by unresolved tissue inflammation and
resulting in tissue dysfunction and organ failure that could ultimately lead to death. A myriad of factors are
thought to contribute to fibrosis and, although it is relatively common, treatments focusing on reversing fibrosis
are few and far between. The process of fibrosis involves a variety of cell types, including epithelial, endothelial,
and mesenchymal cells, as well as immune cells, which have been shown to produce pro-fibrotic cytokines.
Advances in our understanding of the molecular mechanisms of inflammation-driven tissue fibrosis and scar
formation have led to the development of targeted therapeutics aiming to prevent, delay, or even reverse tissue
fibrosis. In this review, we describe promising targets and agents in development, with a specific focus on cy-
tokines that have been well-described to play a role in fibrosis: IL-1, TNF-α, IL-6, and TGF-β. An array of small
molecule inhibitors, natural compounds, and biologics have been assessed in vivo, in vivo, and in the clinic,
demonstrating the capacity to either directly interfere with pro-fibrotic pathways or to block intracellular en-
zymes that control fibrosis-related signaling pathways. Targeting pro-fibrotic cytokines, potentially via a multi-
pronged approach, holds promise for the treatment of inflammation-driven fibrotic diseases in numerous or-
gans. Despite the complexity of the interplay of cytokines in fibrotic tissues, the breadth of the currently ongoing
research targeting cytokines suggests that these may hold the key to mitigating tissue fibrosis and reducing organ
damage in the future.1. Background
Fibrosis is a widespread condition that can affect all areas of the body.
It involves the scarring of tissue, which is often accompanied by
increased tissue inflammation, and results in defective tissue and organ
failure that could lead to death. A myriad of factors are thought to
contribute to fibrosis and, although it is relatively common, treatments
focusing on reversing fibrosis are few and far between. Fibrosis involves a
variety of cells, including immune cells such as monocytes/macrophages
and leukocytes, which are thought to produce pro-fibrotic cytokines
(Wynn and Vannella, 2016). In normal wound healing, these cells coor-
dinate the removal of cellular debris and attract other cell types such as
endothelial cells, epithelial cells and fibroblasts to initiate the wound
healing process. Endothelial cells contribute to revascularizing the new
tissue, fibroblasts differentiate into myofibroblasts and deposit structural
proteins such as collagen, and epithelial cells regenerate the tissue.
However, in fibrosis, dysregulated myofibroblasts can cause excessivehnson).
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evier B.V. This is an open accesscollagen deposition, resulting in the formation of scar tissue and leading
to fibrotic organs (Wynn, 2008). These myofibroblasts can originate from
existing fibroblasts, but also from epithelial or endothelial to mesen-
chymal transition as well as through the differentiation of tissue resident
mesenchymal progenitor cells, i.e. pericytes (Micallef et al., 2012;
Rowley and Johnson, 2014; Kalluri and Weinberg, 2009).
In fibrosis, a number of signaling cascades are modified by changes in
themicroenvironment, triggered by cytokines. Initially, this involves pro-
inflammatory cytokines such as IL-1, IL-6, TNF-α and TGF-β being
released from damaged epithelial cells (Li et al., 1998). This stimulates an
immune response that results in additional cytokines being released from
macrophages (Wynn and Vannella, 2016). The release of these cytokines
results in the activation or deactivation of pathways, including the
PI3K/Akt pathway, NFκB pathway and SMAD/BMP signaling. This in-
creases the formation of scar tissue and tissue remodeling caused by
resident myofibroblasts (Hinz et al., 2012).
As any tissue or organ could be subject to fibrosis; therefore,March 2021
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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improving organ function and overall quality of life in patients. For this
reason, multiple drugs and inhibitors are currently in development for
treating fibrosis in specific organs. However, due to the complexity of the
pathways involved and the various functions of these organ, many
treatments are not effective in all cases of fibrosis. In an effort to address
the inflammatory etiology of organ fibrosis, a number of investigations
have been performed to assess the utility of cytokine inhibition in miti-
gating organ fibrosis. These efforts have mainly focused on four cytokine
families: IL-1, TNF-α, IL-6 and TGF-β. This review will describe the roles
of these cytokines in the development of fibrosis and highlight utility of
cytokine inhibition in reversing tissue scarring (Fig. 1).
2. The IL-1 family
Interleukins are signaling molecules produced by leukocytes and are
crucial mediators of the immune response. Many members of the IL-1
family are regarded as pro-inflammatory interleukins and therefore in-
crease the immune response to stimuli. This increase could drive
inflammation and exacerbate fibrosis. Reversing this effect using IL-1
inhibitors may reduce fibrosis in the effected organ (Fig. 2).
IL-1β is the most abundant cytokine in the IL-1 family and circulates
as the precursor pro-IL-1β. The pro-IL-1β protein is matured by the
NLRP3 inflammasome and the activation of caspase-1 (He et al., 2016).
Caceres et al. (2019) inhibited the NLRP3 inflammasome using the drug
serelaxin, which is a recombinant form of the protein relaxin. They
demonstrated that serelaxin treatment of cardiac myofibroblastsFig. 1. PRISMA flow diagram delineating the search
2
inhibited TLR4, which resulted in the NLRP3 inflammasome being un-
able to form and therefore IL-1β remaining in its inactive form. They also
suggested that this prevented myofibroblast differentiation and reduced
collagen deposition. This study implied that in vivo treatment with ser-
elaxin may reduce remodeling and scar tissue formation in cardiac
fibrosis (Caceres et al., 2019). Serelaxin has also been used to treat
fibrosis in an OVA-driven model of allergic airway disease. It was able to
reduce fibrosis and facilitate bronchodilation, likely through its ability to
encourage collagen turnover through an increase in MMPs, which along
with the degradation of ECM proteins, is able to reduce the effect of other
pro-fibrotic cytokines (Lam et al., 2016, 2018; Royce et al., 2009).
As well as seralaxin, studies have suggested that the drug Empagli-
flozin also targets the formation of the NLRP3 inflammasome. Sukhanov
et al. identified the role of another cytokine (IL-17) on inflammasome
formation and subsequent IL-1β activation (Sukhanov et al., 2021). They
showed that, through the inhibition of IL-17, various downstream effects
can be attenuated, such as the migration and proliferation of aortic
smooth muscle cells in vascular proliferative disease. The association
between IL-17 and IL-1β activation was confirmed through an increase of
IL-1β mRNA and secreted protein, which subsequently induced cell
migration and proliferation. They also highlighted that the relationship
between IL-17 and the NLRP3 inflammasome may be dependent on
NF-κB and AP-1, which are mediated by TRAF3IP2. Empagliflozin
treatment was shown to prevent the increase of IL-1β and NLRP3
expression and reduce the proliferation and migration that was induced
by IL-17 (Sukhanov et al., 2021). Targeting the proliferation and
migration that is seen in vascular proliferative disease as well as manystrategy used in the preparation of this review.
Fig. 2. IL-1 family signaling pathways in fibrosis and the mechanism of action of IL-1 pathway inhibitors.
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damaging effect mesenchymal cells have in inflamed tissue.
A natural inhibitor of IL-1β also exists, known as IL-1Ra, which may
be utilized in its recombinant form (anakinra) to reverse fibrosis. It acts
as a competitive inhibitor and prevents the activation of the IL-1R1 re-
ceptor, therefore preventing the activation of NF-κβ via IL-1β. A recent in
vivo study was performed on mice with alcohol-induced liver disease
showing that treatment with recombinant IL-1Ra reduced organ fibrosis,
assessed by evaluating the expression of PIIINP, a form of procollagen
that is often used as amarker for fibrosis (Lotfy et al., 2019). These results
corroborated an earlier study showing that anakinra reduced levels of
IL-1β in mice with alcoholic liver disease (Petrasek et al., 2012), indi-
cating that this inhibitor may be a potential treatment for
alcohol-induced liver fibrosis.
Another study testing an inhibitor targeting the IL-1β pathway in liver
fibrosis was performed on mice with non-alcoholic steatohepatitis. Bar-
reyro et al. (2015) used the pan-caspase inhibitor emricasan to target3
caspase-1, one of the essential proteins needed for IL-1 maturation. By
assessing markers of liver damage, i.e. aspartate aminotransferase and
alanine aminotransferase, these investigators suggested that emricasan
can reverse liver fibrosis induced by a high-fat diet. Inflammatory
markers were also tested for, including IL-1β, with emricasan-treated
mice expressing significantly less IL-1β when measured by qPCR (Bar-
reyro et al., 2015). This suggests that it is possible to inhibit IL-1β by
preventing its maturation and forcing it to remain in the inactive
pro-IL-1β form.
The arthritis drug auranofin has also been investigated in the treat-
ment of non-alcoholic fatty liver disease (Hwangbo et al., 2020). Through
staining of liver tissue in a mouse model of fatty liver disease, it was
shown that auranofin treatment reduced the number of circulating
macrophages, which would decrease the amount of inflammatory cyto-
kines secreted. It was confirmed via Western blot that auranofin reduced
the secretion of caspase-1 and subsequently IL-1β compared to the con-
trol. This was also shown to be due to the reduction of NLRP3
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mation of the NLRP3 inflammasome in fibrotic liver tissue resulting in
the activation of IL-1β by caspase-1 (Hwangbo et al., 2020). The up-
stream target of auranofin encourages a widespread effect and increased
the effectiveness of the drug.
An existing drug, artesunate, normally used to treat malaria has been
shown to combat fibrotic diseases, specifically hepatic ischemia
(El-Sayed Ghoneim et al., 2020). It has been shown that treatment of
artesunate in rats with hepatic ischemia reduced the expression of the
NLRP3 protein complex as well as caspase-1, the protein responsible for
the activation of IL-1β. This was confirmed via Western blot as well as the
subsequent reduction of circulating IL-1β. This downstream inhibition
was likely to be determined by the disruption of TLR4, TRAF6 and NF-κB
signaling shown via ELISA assay. It was also shown that artesunate has an
overall protective effect against hepatic ischemia as liver injury scores
determined through histopathological staining were significantly low-
ered (El-Sayed Ghoneim et al., 2020). The repurposing of existing drugs
to treat fibrosis is a lucrative pathway in drug development as thorough
safety analyses have already been performed.
Studies have also focused on IL-1β in renal fibrosis. Masola et al.
(2019) performed an in vitro study using human renal proximal tubular
epithelial cells (HK-2) and hepatic stellate cells and (LX-2, i.e. pericytes)
to test the impact of IL-1β inhibition on fibrosis. This study focused on
epithelial-to-mesenchymal transition (EMT) as a driver of fibrosis and a
source of myofibroblasts, which is induced by the release of inflamma-
tory cytokines and growth factors and leads to the overproduction of
collagen and tissue remodeling (Fragiadaki and Mason, 2011). It was
observed that treatment with IL-1β induced EMT, demonstrated by
increased expression of the fibrotic markers fibronectin, vimentin and
α-smooth muscle actin (α-SMA). Crucially, treatment with the IL-1β in-
hibitor canakinumab reversed the expression of these markers as well as
that of a critical mediator of EMT, MMP-2. Moreover, canakinumab also
attenuated the induction of a myofibroblast phenotype caused by TGF-β
treatment, suggesting that the inhibition is not specific to IL-1β, indi-
cating that this therapeutic modality may also be promising for resolving
kidney fibrosis (Masola et al., 2019).
Renal ischemia also results in inflammation, oxidative stress and the
induction of fibrosis. Taraxasterol, the active compound in the traditional
herbal medicine Taraxacum officinale, has been investigated for its anti-
inflammatory effects (Li et al., 2020). In mice with acute kidney injury,
taraxasterol treatment decreased the pathological score of renal tubular
injury, indicating a reduction in cell necrosis, tubular dilation and the
infiltration of inflammatory cells. This suggests that taraxasterol must
interrupt upstream inductors of fibrosis. In this model of kidney injury,
macrophage numbers significantly increased along with interstitial
fibrosis; these were both attenuated with taraxasterol treatment. along
with a reduction in serum IL-1β. This was likely achieved by a reduction
in ERK and JNK phosphorylation, thus blocking the downstream effects
of IL-1β. It was also suggested that reactive oxygen species are produced
following IL-1β signaling, which was abrogated by taraxasterol via the
inhibition of MAPK signaling (Li et al., 2020). The combined approach
with taraxasterol mitigating both inflammation and oxidative stress
seems to be a promising mode of action in reducing tissue remodeling in
fibrosis.
Another natural anti-fibrotic drug being explored is andrographolide,
a compound isolated from Andrographis paniculate; this natural resource
has been traditionally used to treat inflammation, although the mecha-
nism of action was unknown. Gupta et al. investigated the effects of this
active compound in a mouse model of arthritis manifested as an increase
in the infiltration of immune cells in the hind limbs (Gupta et al., 2020).
Histopathological analysis suggested that treatment with andrographo-
lide reduced the number of immune cells present and encouraged the
regrowth of the synovial lining. Mechanistically, it was found that
andrographolide attenuated NF-κB translocation into the nucleus,
thereby inducing immune suppression. Along with this, the phosphory-
lation of p38 and the concentration of serum IL-1β were significantly4
reduced following andrographolide treatment. This inhibition was
shown to decrease paw edema and improve the presentation of arthritic
fibrosis (Gupta et al., 2020). By targeting NF-κB, which is involved in
many pro-inflammatory and pro-fibrotic signaling cascades, androgra-
pholide may have a beneficial impact in a number of inflammatory and
fibrotic diseases.
IL-1β has also been identified as one of the most significant triggers in
fibrosis following myocardial infarction. It has been highlighted that IL-
1β may contribute to fibroblast differentiation, which would contribute
to disordered tissue remodeling. Treating mice with the small molecule
MCB-613, a steroid receptor coactivator stimulator,was shown to
decrease IL-1β mRNA expression in cardiac fibroblasts following
myocardial infarction via single cell analysis (Mullany et al., 2020). This
was also shown in an inflamed microenvironment induced by M1 mac-
rophages. Mullany et al. suggested that MCB-613 works via the upregu-
lation of SRC-3, which is an inhibitor of IL-1β activity in macrophages.
This, in turn, would reduce the concentration of IL-1β in the microenvi-
ronment, thus reducing the differentiation of cardiac fibroblasts. This
was mechanistically confirmed with in vitro experiments. Treatment
with MCB-613 was shown to greatly reduce fibrotic tissue in murine
hearts following myocardial infarction, illustrating the overall effect of
IL-1β inhibition and the reduction of inflammation in the microenvi-
ronment (Mullany et al., 2020). This study highlights the contribution of
fibroblasts in cardiac remodeling as well as the potential of small mole-
cule stimulators in the reduction of fibrotic tissue.
IL-33 is another member of the IL-1 family of pro-inflammatory in-
terleukins. It has long been thought to contribute to fibrosis, in particular
in allergic inflammation. This is due to its ability to activate immune cells
such as macrophages, eosinophils, cytotoxic T cells, and group 2 innate
lymphoid cells upon cell damage (Chan et al., 2019; Kondo et al., 2008;
Bonilla et al., 2012). These activated immune cells promote the fibrotic
microenvironment and encourages the subsequent production of further
pro-fibrotic cytokines. The inhibition of IL-33 would theoretically pre-
vent the downstream activation of pro-fibrotic cytokines thus reducing
fibrosis. One study has investigated the role of IL-33 expression in rats
with chronic heart failure (Wang et al., 2017). The IL-33/ST2 signaling
axis was inhibited using the microRNA miR487b, which was found to
reduce the expression of the IL-33 protein, resulting in improved cardiac
morphology and reduced collagen expression in an in vivo model of
chronic heart failure induces by coronary artery occlusion. The use of
microRNAs to inhibit cytokines and the downstream signaling pathways
may therefore be a fruitful avenue to pursue in ongoing efforts to
attenuate tissue fibrosis.
3. TNF-α
TNF-α is produced during inflammation by immune cells such as
macrophages and monocytes. TNF-α has various roles within the body,
including pathogen resistance, anti-tumor immunity and sleep regula-
tion. It affects these processes by activating a variety of pathways,
including NF-κB, Erk, MAPK and PLA2 (Idriss and Naismith, 2000). The
important roles of TNF-α in regulating inflammation explains why it is
also involved in fibrosis as the two often come hand in hand (Fig. 3).
Following organ transplantation, extensive fibrosis often occurs, i.e.
chronic transplant rejection. Zhou et al. (2019) investigated the effect of
a TNF-α inhibitor to prevent EMT, a key driver of interstitial renal
fibrosis. They showed that treatment of HK-2 cells with TNF-α caused an
increase in the EMT markers α-SMA and fibronectin via the activation of
Smurf1, an e3 ubiquitin ligase that has been found to be involved in cell
migration and polarity as well as EMT through its interaction with the
TGF-β canonical pathway and NF-κβ signaling (Zhou et al., 2019). The
anti-cancer drug bortezomib, a proteasome inhibitor, has also been
shown to target Smurf1, a HECT-type E3 ubiquitin ligase that plays a
critical role in vertebrate development (Koefoed et al., 2018), thereby
reducing the phosphorylation of Akt and inhibiting EMT. Moreover,
bortezomib was found to reduce inflammation and fibrosis after
Fig. 3. TNF-α signaling pathways in fibrosis and the mechanism of action of TNF-α pathway inhibitors.
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gests that existing cancer drugs may be useful tools in mitigating fibrosis
(Wishart et al., 2006).
As previously mentioned, TNF-α can activate the MAPK pathway via
NF-κB, a critical pathway mediating inflammation. In addition, TNF-α is
thought to interact with TLR4 and modulate its expression, with varia-
tions in TLR4 signaling being an important factor in many diseases
(Simonaro et al., 2010). Using the unilateral ureteric obstruction (UUO)
mouse model of renal interstitial fibrosis, Li et al. (2019) tested the
natural drug salidroside and its ability to inhibit the NF-κB pathway.
They showed that salidroside reduced the inflammatory markers TNF-α,
IL-6 and IL-1β in vivo. It also reduced the levels of both collagen I and III
in the ECM and reduced EMT via the downregulation of TGF-β, α-SMA
and vimentin. They postulated that salidroside had these effects by
inhibiting TLR4, which subsequently reduced the expression of the
downstream molecules NF-κB and p-ERK, shown via Western blot (Li
et al., 2019).5
Naturally sourced compounds have also been suggested to affect the
TNF-α/NFκB pathway. The drug phillygenin is obtained from the plant
Forsythia suspensa and is often used in traditional Chinese medicine. In an
in vitro study investigating the induction of a fibrotic phenotype in LX-2
hepatic stellate cells, phillygenin reduced the expression of IL-1β, IL-6
and TNF-α, suggesting that it has anti-inflammatory properties (Hu
et al., 2020). Western blot experiments also indicated that treatment with
phillygenin mitigated the induction of fibrosis markers, as it reduced the
expression of α-SMA and collagen 1 (Hu et al., 2020). It was also found in
this study that phillygenin binds directly with TLR4 in order to inhibit the
downstream signaling cascade (Hu et al., 2020). This study highlights the
possibility of using natural drugs to reverse tissue fibrosis and
inflammation.
Periodontal fibrosis has been treated using the flavonoid cynaroside
and the mechanisms behind its activity have been explored (Lee et al.,
2020). The effects of cymaroside were tested in vitro on human peri-
odontal ligament cells. LPS was used as an inductor of fibrosis and
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were reversed with cymaroside, observed viaWestern blot, and were also
observed in RAW264.7 cells. It was hypothesized that this effect was
mediated through the inhibition of NF-κB, as cynaroside prevented the
translocation of the NF-κB p65 subunit to the nucleus. This prevent the
resulting signalling cascade and impaired the induction of fibrosis. It was
also shown that treatment with cynaroside encouraged the differentia-
tion of periodontal ligament cells into a more osteogenic morphology, so
this flavonoid may be useful for repairing damaged teeth (Lee et al.,
2020). By preventing the action of TNF-α through the arrest of NF-κB as
well as reforming bone tissue, cynaroside is a promising treatment for
periodontal fibrosis.
Chronic respiratory disease often involves severe inflammation and,
in chickens, can be caused by mycoplasma infection. Zou et al. (2020)
proposed using polydatin, a resveratrol glycoside isolated from Polyg-
onum cuspidatum, to treat this inflammation. Damaged lungs showed
increased numbers of inflammatory cells, shedding of epithelial cells and
alveolar congestion. These changes were not present in lungs treated
with polydatin, suggesting a molecular intervention with this
anti-fibrotic compound. Polydatin was also shown to reduce TLR6
expression in a dose-dependent manner. TLR6 activates the NF-κB
pathway, with Zou showing that polydatin treatment resulted in a
decrease in nuclear NF-κB translocation. Proinflammatory cytokines,
including TNF-α, were also markedly decreased following polydatin
treatment, suggesting that polydatin successfully blocks the effect of
proinflammatory cytokines (Zou et al., 2020). Upstream targeting by
polydatin allows the inhibition of a variety of cytokines and thus further
reduces the impact of inflammation on tissue morphology.
Opuntiol, the active ingredient from Opuntia ficus-indica, is known for
its anti-UV properties and is being investigated as a treatment against
UVA-induced skin fibrosis (Kandan et al., 2020). Overall, opuntiol
reduced the clinical score of fibrosis severity in mice following UVA
exposure. In addition, pretreatment with opuntiol prevented epidermal
hyperplasia and loss of collagen. This suggests that opuntiol has a mo-
lecular protective effect which results in the prevention of UV damage.
Using Western blot, the location of NF-κB and AP-1 was determined,
demonstrating that opuntiol prevented the nuclear translocation of
NF-κB and AP-1, thereby preventing transcription. With immunohisto-
chemistry, it was highlighted that topical treatment with opuntiol pre-
vented the build-up of inflammatory proteins such as TNF-α, COX-2 and
iNOS. This suggests that the blockade of the NF-κB prevented
TNF-α-mediated inflammation from further exacerbating fibrosis (Kan-
dan et al., 2020). The effect of UV on pro-inflammatory cytokines was
effectively prevented by opuntiol, suggesting that it may be a good
topical treatment for UV-induced fibrosis.
Son et al. highlighted the positive effects of paclitaxel on diabetic
nephropathy via targeting TNF-α and TLR4 (Son et al., 2020). An in vitro
study was carried out using podocytes to simulate diabetic nephropathy.
Podocyte injury induced by palmitate exposure increased the mRNA
levels of TNF-α and TLR4, but this increase was abrogated by treatment
with paclitaxel. Along with this, reactive oxygen species and NOX4,
which controls reactive oxygen species production, were increased after
injury and reduced following treatment. This intervention may have
contribute to a reduction in podocyte damage, as paclitaxel treatment
prevented F-actin rearrangement, reduced VEGF mRNA levels and
increased nephrin expression (Son et al., 2020).
N-acetyl cysteine is thought to inhibit the formation of ROS, but has
been suggested to also have an anti-fibrotic effect. In a study by Honma
et al., renal interstitial fibrosis was simulated in mice in order to inves-
tigate the effect of N-acetyl cysteine on renal fibrosis (Honma et al.,
2020). The overexpression of TNF-α observed in the fibrotic kidney was
attenuated following N-acetyl cysteine treatment, along with a reduction
in themRNA levels of fibrosis-associated collagen III. TheMAPK pathway
was also affected by N-acetyl cysteine, as this intervention reduced
ERK1/2 phosphorylation, although the JNK and p38 pathways were not
affected. Honma et al. concluded that the intervention with N-acetyl6
cysteine contributed to a reduction in TNF-α and subsequent reduction in
collagen production (Honma et al., 2020). As ERK1/2 is a member of
several cytokine pathways, this downstream intervention may be key to
effectively combating fibrosis.
Clinical trials have been undertaken using the TNF-α inhibitor eta-
nercept in order to treat cytotoxic T lymphocyte-mediated severe cuta-
neous adverse reactions (SCARs) (Wang et al., 2018). It was hypothesized
that TNF-α was responsible for the heightened immune response in
SCARs as well as the death of keratinocytes. As etanercept is a TNF-α
antagonist, it was able to reduce the levels of TNF-α as well as the cell
death mediator granulysin both in vitro and in vivo. In human trials,
Wang et al. also demonstrated that etanercept treatment caused skin
lesions to heal faster and with less inflammation than with standard
corticosteroid treatment. They also showed that etanercept treatment
increased the population of regulatory T cells in the lesion, which also
reduced patient mortality (Wang et al., 2018). The ability of TNF-α to
modulate the immune system under inflammatory and fibrotic condi-
tions highlights the possibility of targeting TNF-α for anti-inflammatory
and anti-fibrotic therapies.
4. IL-6
One of the downstream mediators of the aforementioned IL-1 family
is the inflammatory interleukin IL-6 (Fig. 4), which plays an active role in
the modulation and activation of the immune response; defects in IL-6
signaling play a role in many inflammatory and autoimmune diseases
(Hirano, 2010). IL-6 activates the JAK/STAT3 pathway and the
SHP2/Gab/MAPK pathway and interacts with the NLRP3 inflammasome
(Hirano, 2010; Del Campo et al., 2018). Its ability to induce monocyte
differentiation into macrophages and activate Th2 and Th17 immune
cells also indicates its influence on inflammation and fibrosis (Su et al.,
2017; Fielding et al., 2014). The activation of Th2 and Th17 can be
explored using different models of fibrosis, with more mild fibrosis being
Th2-driven, whilst severe fibrosis is characterized by Th17 responses,
more often seen in unresolved, chronic infections and inflammatory
diseases (Zhang and Zhang, 2020). For example, the house dust mite
model of allergic airway disease induces a mainly Th2 immune response,
but extended aeroallergen exposure leads to a more Th17-skewed
response with extensive tissue remodeling characterized by EMT
(Johnson et al., 2004, 2011, 2015).
With the signaling pathways of IL-6 being so varied, there have been
several different methods of intervention when therapeutically targeting
IL-6. A study by Chou et al. (2018) investigated the effects of IL-6 in
aldosterone-induced cardiac fibrosis. They used a natural existing in-
hibitor of IL-6, sgp130, which can block IL-6 and its soluble form from
binding and inducing the trans-signaling pathway in endothelial cells. By
analyzing the expression of fibronectin and collagen-1, they suggested
that this inhibitor mitigates fibrosis promoted by IL-6. In vivo, they also
showed that recombinant gp130 decreased cardiac fibrosis by observing
reduced ventricular fibrosis following aldosterone infusion in mice (Chou
et al., 2018). This study highlighted the impact of IL-6 on fibrosis and the
potential for therapeutics that interrupt the IL-6 trans-signaling pathway.
Fatty liver disease is another fibrotic condition that is exacerbated by
IL-6. In rats with fatty liver disease, serum levels of IL-6 increased
significantly, but were decreased following lycopene treatment (Saeeda
et al., 2020). Similarly, NF-κB levels were increased in diseased tissue
and decreased with lycopene. Lycopene treatment also prevented struc-
tural changes such as increased α-SMA expression. Further staining also
concluded that lycopene reduced the number in inflammatory cells
present in the effected tissue and mitigated collagen deposition. Saeed
et al. concluded that IL-6 levels are an indicator of insulin resistance and
liver damage, and that a reduction in circulating IL-6 leads to a reduction
in NF-κB activation and therefore a reduction in structural remodeling
(Saeeda et al., 2020). With lycopene also targeting insulin resistance as
well as pro-inflammatory cytokine signaling, this two-pronged approach
may be an effective treatment for fatty liver diseases and associated
Fig. 4. IL-6 signaling pathways in fibrosis and the mechanism of action of IL-6 pathway inhibitors.
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Renal fibrosis is also affected by IL-6 signaling and studies have
identified a tocilizumab mimotope that can target the IL-6 receptor in
order to suppress this signaling pathway (Yang et al., 2020). Via a vaccine
strategy, the mimotope was administered to mice with renal fibrosis
established using the UUO model in order induce inhibitory antibodies
that target IL-6R. Mimotope treatment decreased levels of fibronectin,
collagen and α-SMA compared to untreated diseased tissue via the
modulation of IL-6 signaling. This treatment also suppressed the differ-
entiation of macrophages in the kidneys, further reducing the secretion of
pro-inflammatory cytokines. Vaccination also had downstream effects, as
it reduced the phosphorylation of ERK, thereby preventing that pathway
from contributing to fibrosis. Further injury to the kidney could also be at
least partly prevented by the tocilizumabmimotope, as it slightly reduced
the levels of ferroptosis, which leads to additional kidney injury.
Although the mimotopes successfully inhibited pERK, no change was
observed in the levels of phosphorylated STAT3, so only part of the IL-67
pathway was successfully inhibited (Yang et al., 2020). Despite this, the
effects of the tocilizumabmimotope showed promising effects in terms of
preventing kidney fibrosis.
5. TGF-β
It is widely recognized that TGF-β is one of the main cytokines
involved in fibrosis (Fig. 5). It is upregulated in most fibrotic diseases;
however, paradoxically, it also has anti-inflammatory effects. This is due
to two major signaling pathways, i.e. the canonical pathway mediated by
a cascade of Smad protein interactions and the non-canonical pathway
with activation of mTOR, Erk, JNK and p38 signaling. However, due to its
widespread roles in proliferation, differentiation and various other ho-
meostatic functions, inhibiting TGF-β upstream may induce many side
effects. Therefore, any drugs targeting TGF-β are likely to instead target
the Smad signaling pathway (Kubiczkova et al., 2012; Biernacka et al.,
2011; Meng et al., 2016).
Fig. 5. TGF-β signaling pathways in fibrosis and the mechanism of action of TGF-β pathway inhibitors.
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rhamnetin from the leaves of the plant Oenanthe javanica (Yang et al.,
2016). They showed that treatment with 50–100 μM isorhamnetin
reduced the expression of fibrotic markers α-SMA and PAI-1 in
TGF-β-treated hepatic stellate cells. Isorhamnetin also decreased Smad
binding element activity and greatly inhibited the phosphorylation of
Smad2 and Smad3, suggesting that it targets this stage of the canonical
TGF-β signaling cascade. They also highlighted the protective effect of
isorhamnetin against oxidative stress by preventing TGF-β-induced
reactive oxygen species production and by activating the antioxidant
protein Nrf2 (Yang et al., 2016). This two-pronged approach is promising
as it combats two triggers of fibrosis whilst not blocking TGF-β activity
completely, which should reduce possible side effects.8
Another study on the role of TGF-β in liver fibrosis utilized a mouse
model to investigate the relationship between TGF-β and another mem-
ber of the TGF family, BMP7 (Zou et al., 2019). These authors observed
that mice with induced liver fibrosis had upregulated levels of TGF-β and
Smad3, and downregulated BMP7 and Smad1/5/8. This suggests that
Smad1/5/8 signaling might inhibit the fibrotic effects of TGF-β via BMP7
(Guo et al., 2017). They also showed that, in vitro, a high dose BMP7
delivered to TGF-β-treated hepatic stellate cells reduced the production
of the myofibroblast markers α-SMA and collagen I and moreover
inhibited p38-induced migration and proliferation. This suggests that
BMP7, via Smad1/5/8, inhibits hepatic stellate cell activation and miti-
gates fibrosis through a reduction in activated myofibroblasts (Zou et al.,
2019). The use of exogenous proteins and existing inhibitory signaling
R. Bignold, J.R. Johnson Current Research in Pharmacology and Drug Discovery 2 (2021) 100023cascades highlights further targets for therapeutic intervention without
having to introduce molecules that may have off-target effects.
Along with liver fibrosis, kidney fibrosis is another condition which
often presents with elevated levels of TGF-β. Lu et al. hypothesized that
the naturally occurring compound asperulosidic acid, which has been
reported to have anti-fibrotic and anti-inflammatory effects, may inter-
fere with TGF-β signaling in order to ameliorate kidney fibrosis (Lu et al.,
2019). These authors found that, in rats with unilateral ureteral
obstruction, asperulosidic acid reduced markers of renal damage, blood
urea nitrogen, uric acid and urinary protein, suggesting that the treat-
ment reduced kidney fibrosis overall. More specifically, they showed that
asperulosidic acid decreased the expression of the inflammatory cyto-
kines TNF-α, IL-1β and IL-6, suggesting that asperulosidic acid can
modulate inflammation through the inhibition of NF-κB. Asperilosidic
acid also reduced the expression of TGF-β and α-SMA, likely due to the
regulation of pro-fibrotic Smad2/3/4 signaling (Lu et al., 2019). By
inhibiting both the inflammatory pathway and TGF-β-induced pathway,
the overall inhibition of fibrosis should be more effective than treatments
that only target one arm of the response. By showing that this treatment
has an effect on the overall pathogenesis of kidney fibrosis, it highlights
the potential of this treatment and therefore the importance of these
targeted processes on the development of fibrosis.
A different acid which is thought to interfere with TGF-β signaling is
salvanic acid B. A study performed in a mouse model of myocardial
fibrosis confirmed that TGF-β and Smad2/3 were increased during
fibrosis, with the antifibrotic Smad7 being decreased (Gao et al., 2019).
Following salvanic acid B treatment, this was reversed with decreased
TGF-β and Smad2/3 expression and increased Smad7 levels on the mRNA
and protein levels. The morphology of cardiac fibroblasts was also
investigated, with the spindle shape of TGF-β-treated fibroblasts being
modulated by salvanic acid B. Salvanic acid B was also shown to reduce
the expression of the extracellular matrix enzymes MMP-2 and MMP-9,
indicating that TGF-β induces modulation of the extracellular matrix, a
hallmark of fibrosis, and that this can be attenuated by salvanic acid B
treatment (Gao et al., 2019). This study suggests that the inhibition of the
Smad2/3 protein complex in the TGF-β canonical signaling pathway is
key to reducing the effect of TGF-β on the extracellular matrix and
perhaps the formation of myofibroblasts. It also touched upon harnessing
Smad7, a natural regulator of the TGF-β pathway. By controlling this
regulator of TGF-β signaling, it may be possible to dampen its effects in
fibrosis.
TGF-β also contributes to interstitial fibrosis in the kidneys. Wang
et al. explored the effects of the dihydroflavonoid naringin on TGF-
β-induced fibrotic renal epithelial cells (Wang et al., 2021). Cell fibrosis,
characterized by the expression of α-SMA, was decreased following
treatment with naringin, highlighting its ability to inhibit the fibrotic
effect of TGF-β. By targeting the canonical TGF-β pathway and the
phosphorylation of Smad2/3, fibrosis was markedly reduced, and
downstream mediators of other pro-fibrotic cascades such as NF-κB were
also suppressed. To corroborate this, mRNA levels of fibrotic markers
TGF-β, α-SMA and collagen 1 were measured in vivo following the in-
duction of renal fibrosis with the UUO model. Treatment with naringin
significantly reduced all fibrotic markers both in vivo and in vitro,
highlighting its effectiveness as an anti-fibrotic drug. Naringin moreover
improved the atrophy of kidney tubular cells following fibrotic injury,
which suggests that it may have a clinically useful effect (Wang et al.,
2021).
The diabetic drug metformin has been tested in chronic kidney dis-
eases to explore its potential as a TGF-β-targeting anti-fibrotic interven-
tion (Yi et al., 2021). Metformin treatment after adenine-induced renal
injury in mice significantly decreased urinary albumin levels, suggesting
an improvement in kidney function. It was also shown to decrease
fibrosis, as the mRNA levels of both collagen 4 and fibronectin were
decreased, highlighting a reduction in extracellular matrix protein
accumulation and the prevention of fibrosis. Inflammation was also
reduced following metformin treatment, as the number of activated9
macrophages decreased as well as the levels of macrophage chemotactic
protein, which is often used as a marker for renal inflammation. Using
Western blot, Yi et al. showed that metformin inhibited the phosphory-
lation of Smad3 as well as ERK1/2 and p38, thus suppressing both the
canonical and non-canonical TGF-β signaling pathways (Yi et al., 2021).
By targeting both arms of the TGF-β signaling pathway, metformin may
have a considerable effect in terms of mitigating fibrosis.
6. Outlook
There are many different types of cytokine inhibitors currently being
investigated as potential treatments for fibrosis in various organs. The
variety of strategies and targets discussed here indicates the scope of this
area of research and the complexity of the systems at play in fibrosis.
Some treatments do not directly inhibit the target cytokine and instead
target a molecule upstream (in the case of emericasan and serelaxin),
thereby preventing the active cytokine from being produced, or down-
stream mediators (e.g. bortezomib and salidroside) to prevent the
signaling cascade and the action of the cytokine from occurring in full.
There is also a possibility of harnessing the body’s innate defenses, such
as in the case of IL-1Ra and BMP7, and either increasing or modulating
their effects in order to combat fibrosis. There is also an increasing
number of natural, plant-based compounds being explored for their anti-
fibrotic properties, including phillygenin, lycopene and isohamnetin,
which have been used in herbalism and traditional medicine systems and
have been more recently shown to have scientific promise in the case of
treating fibrosis. Despite the complexity of the interplay of cytokines in
fibrotic tissues, the breadth of the currently ongoing research targeting
cytokines suggests that these may hold the key to mitigating tissue
fibrosis and reducing organ damage in the future.
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